GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » Accumulated other comprehensive income (loss)

MREO (Mereo BioPharma Group) Accumulated other comprehensive income (loss) : $-15.29 Mil (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Mereo BioPharma Group Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Mereo BioPharma Group's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2025 was $-15.29 Mil.

Mereo BioPharma Group's quarterly Accumulated other comprehensive income (loss) declined from Sep. 2024 ($-11.10 Mil) to Dec. 2024 ($-18.85 Mil) but then increased from Dec. 2024 ($-18.85 Mil) to Mar. 2025 ($-15.29 Mil).

Mereo BioPharma Group's annual Accumulated other comprehensive income (loss) increased from Dec. 2022 ($-21.69 Mil) to Dec. 2023 ($-17.49 Mil) but then declined from Dec. 2023 ($-17.49 Mil) to Dec. 2024 ($-18.85 Mil).

Mereo BioPharma Group Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Mereo BioPharma Group's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Accumulated other comprehensive income (loss) Chart

Mereo BioPharma Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 181.56 184.76 -21.69 -17.49 -18.85

Mereo BioPharma Group Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.28 -18.28 -11.10 -18.85 -15.29

Mereo BioPharma Group Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Mereo BioPharma Group Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
PRTA CTMX CKPT FULC AURA ERAS FTRE OLMA VIGL ABSI VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
0A9G:UK MAH0:Germany
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Website
https://www.mereobiopharma.com
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).